{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:12:49Z","timestamp":1777029169914,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013428","name":"Stichting Spieren voor Spieren","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","award":["956185"],"award-info":[{"award-number":["956185"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OB21-01"],"award-info":[{"award-number":["W.OB21-01"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejpn.2022.12.003","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T20:28:18Z","timestamp":1670358498000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1526-045X","authenticated-orcid":false,"given":"F.E.V.","family":"Scheijmans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Cuppen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8868-7155","authenticated-orcid":false,"given":"M.M.","family":"Zwartkruis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Signoria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"van Ekris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Asselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.I.","family":"Wadman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-9820","authenticated-orcid":false,"given":"E.F.","family":"Knol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.L.","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2330-9444","authenticated-orcid":false,"given":"E.J.N.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2022.12.003_bib1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: controversies and challenges","volume":"11","author":"Mercuri","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpn.2022.12.003_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ejpn.2022.12.003_bib3","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A\u00a0single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejpn.2022.12.003_bib4","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A\u00a0single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejpn.2022.12.003_bib5","doi-asserted-by":"crossref","first-page":"fcaa075","DOI":"10.1093\/braincomms\/fcaa075","article-title":"Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy","volume":"2","author":"Wadman","year":"2020","journal-title":"Brain Commun."},{"key":"10.1016\/j.ejpn.2022.12.003_bib6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/gt.2017.34","article-title":"How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy","volume":"24","author":"Singh","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejpn.2022.12.003_bib7","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejpn.2022.12.003_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejpn.2022.12.003_bib9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpn.2022.12.003_bib10","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejpn.2022.12.003_bib11","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2022.12.003_bib12","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejpn.2022.12.003_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.braindev.2019.12.006","article-title":"Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: a case report focusing on the neurofilament light chain in cerebrospinal fluid","volume":"42","author":"Tozawa","year":"2020","journal-title":"Brain Dev."},{"key":"10.1016\/j.ejpn.2022.12.003_bib14","doi-asserted-by":"crossref","first-page":"E79","DOI":"10.1002\/mus.27042","article-title":"Possible recurrent aseptic meningitis associated with nusinersen therapy","volume":"62","author":"Moshe-Lilie","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejpn.2022.12.003_bib15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3389\/fneur.2019.00735","article-title":"Routine cerebrospinal fluid cytology reveals unique inclusions in macrophages during treatment with nusinersen","volume":"10","author":"Gingele","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejpn.2022.12.003_bib16","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1111\/ijlh.13392","article-title":"Unusual inclusions in cerebrospinal fluid macrophages of spinal muscular atrophy patients treated with nusinersen","volume":"43","author":"Machacek","year":"2021","journal-title":"Int. J. Lab Hematol."},{"key":"10.1016\/j.ejpn.2022.12.003_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000518005","article-title":"Cytochemical characterization of cerebrospinal fluid macrophage inclusions in pediatric patients receiving intrathecal nusinersen (SPINRAZA(R)) for spinal muscular atrophy","volume":"66","author":"Schafernak","year":"2022","journal-title":"Acta Cytol."},{"key":"10.1016\/j.ejpn.2022.12.003_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","article-title":"Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0-4","volume":"88","author":"Wadman","year":"2017","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejpn.2022.12.003_bib19","doi-asserted-by":"crossref","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","article-title":"Muscle strength and motor function in adolescents and adults with spinal muscular atrophy","volume":"95","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2022.12.003_bib20","doi-asserted-by":"crossref","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","article-title":"Population-based analysis of survival in spinal muscular atrophy","volume":"94","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2022.12.003_bib21","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/PEP.0b013e3182351f04","article-title":"Validation of the Children's hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND)","volume":"23","author":"Glanzman","year":"2011","journal-title":"Pediatr. Phys. Ther."},{"key":"10.1016\/j.ejpn.2022.12.003_bib22","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1177\/0883073811420294","article-title":"Validation of the expanded Hammersmith functional motor scale in spinal muscular atrophy type II and III","volume":"26","author":"Glanzman","year":"2011","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.ejpn.2022.12.003_bib23","unstructured":"EMA. Spinraza-epar-product-information_en2018: 1-31."},{"key":"10.1016\/j.ejpn.2022.12.003_bib24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cyto.2017.10.021","article-title":"Effect of anticoagulants on 162 circulating immune related proteins in healthy subjects","volume":"106","author":"Scholman","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.ejpn.2022.12.003_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cyto.2015.10.001","article-title":"CSF cytokines\/chemokines as biomarkers in neuroinflammatory CNS disorders: a systematic review","volume":"77","author":"Kothur","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.ejpn.2022.12.003_bib26","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.bbamcr.2014.05.014","article-title":"Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease","volume":"1843","author":"Turner","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejpn.2022.12.003_bib27","first-page":"4061","article-title":"A\u00a0severe mouse model of spinal muscular atrophy develops early systemic inflammation","volume":"27","author":"Wan","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejpn.2022.12.003_bib28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41556-018-0151-y","article-title":"Denervation-activated STAT3-IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis","volume":"20","author":"Madaro","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejpn.2022.12.003_bib29","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/BF03401830","article-title":"Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes","volume":"6","author":"Baron-Delage","year":"2000","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejpn.2022.12.003_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039113","article-title":"Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy","volume":"7","author":"Sareen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpn.2022.12.003_bib31","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/rheumatology\/keaa270","article-title":"Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk","volume":"60","author":"Wienke","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejpn.2022.12.003_bib32","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1523\/JNEUROSCI.3472-16.2017","article-title":"Decreased motor neuron support by SMA astrocytes due to diminished MCP1 secretion","volume":"37","author":"Martin","year":"2017","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejpn.2022.12.003_bib33","doi-asserted-by":"crossref","first-page":"25782","DOI":"10.1074\/jbc.M112.362830","article-title":"Human axonal survival of motor neuron (a-SMN) protein stimulates axon growth, cell motility, C-C motif ligand 2 (CCL2), and insulin-like growth factor-1 (IGF1) production","volume":"287","author":"Locatelli","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejpn.2022.12.003_bib34","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.omtm.2021.10.011","article-title":"Implications of circulating neurofilamentsfor spinal muscular atrophytreatment early in life: a case series","volume":"23","author":"Alves","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ejpn.2022.12.003_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.583877","article-title":"New therapeutics options for pediatric neuromuscular disorders","volume":"8","author":"Flotats-Bastardas","year":"2020","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ejpn.2022.12.003_bib36","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nri2711","article-title":"The regulation of IL-10 production by immune cells","volume":"10","author":"Saraiva","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejpn.2022.12.003_bib37","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/08830185.2012.762361","article-title":"IL-10-producing lymphocytes in inflammatory disease","volume":"32","author":"Yao","year":"2013","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.ejpn.2022.12.003_bib38","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jnc.14953","article-title":"Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy","volume":"153","author":"Kessler","year":"2020","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejpn.2022.12.003_bib39","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1111\/jcmm.16802","article-title":"Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen","volume":"25","author":"Johannsen","year":"2021","journal-title":"J.\u00a0Cell Mol. Med."},{"key":"10.1016\/j.ejpn.2022.12.003_bib40","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3389\/fneur.2019.01179","article-title":"Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen","volume":"10","author":"Wurster","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejpn.2022.12.003_bib41","first-page":"11","article-title":"Cerebrospinal fluid parameters in antisense oligonucleotide-treated adult 5q-spinal muscular atrophy patients","author":"Muschen","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejpn.2022.12.003_bib42","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ejpn.2017.03.006","article-title":"Validated age-specific reference values for CSF total protein levels in children","volume":"21","author":"Kahlmann","year":"2017","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ejpn.2022.12.003_bib43","first-page":"2129","article-title":"NFL is a marker of treatment response in children with SMA treated with nusinersen","volume":"266","author":"Olsson","year":"2019","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ejpn.2022.12.003_bib44","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1111\/jcmm.14939","article-title":"Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on Spinal Muscular Atrophy type 3 patients","volume":"24","author":"Faravelli","year":"2020","journal-title":"J.\u00a0Cell Mol. Med."},{"key":"10.1016\/j.ejpn.2022.12.003_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419846058","article-title":"Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment","volume":"12","author":"Wurster","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.ejpn.2022.12.003_bib46","first-page":"36","article-title":"Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen","volume":"267","author":"Wurster","year":"2020","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ejpn.2022.12.003_bib47","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ejpn.2022.12.003_bib48","article-title":"Assessment of cerebral spinal fluid biomarkers and microRNA-mediated disease mechanisms in spinal muscular atrophy patient samples","author":"Welby","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejpn.2022.12.003_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/glia.24153","article-title":"Viral mediated knockdown of GATA6 in SMA iPSC-derived astrocytes prevents motor neuron loss and microglial activation","author":"Allison","year":"2022","journal-title":"Glia"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379822001684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379822001684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:40:21Z","timestamp":1761072021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379822001684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":49,"alternative-id":["S1090379822001684"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2022.12.003","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2022.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}